Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kathleen Anthony

Physician Assistant Marksville, LA Physician Assistant

NPI 1386078095 CMS profile 10825312

5541 Highway 1, Marksville, LA 71351

Open in the dashboard

General payments

$9,929

514 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kathleen Anthony of Marksville, LA is reported in the CMS Open Payments database as having received $9,929 across 514 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $132 7
2024 General $1,720 102
2023 General $2,121 102
2022 General $2,671 143
2021 General $3,285 160

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kathleen Anthony
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kathleen Anthony were reported at $132. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kathleen Anthony Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,285 $132 $37–$438 $132
2022 $2,671 $155 $48–$522 $149
2023 $2,121 $167 $52–$557 $160
2024 $1,720 $178 $55–$600 $164
2025 $132 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $2,351 127 payments
  2. AbbVie, Inc. $1,873 94 payments
  3. Janssen Biotech, Inc. $951 55 payments
  4. Novartis Pharmaceuticals Corporation $918 53 payments
  5. UCB, Inc. $730 37 payments
  6. Flexion Therapeutics, Inc. $498 4 payments
  7. Mallinckrodt Hospital Products Inc. $352 17 payments
  8. Lilly USA, LLC $323 18 payments
  9. Pfizer Inc. $307 20 payments
  10. E.R. Squibb & Sons, L.L.C. $290 16 payments
  11. Other $1,338 73 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,795 511 payments
  2. Education $135 3 payments
Products named General payments · program years 2021–2025
  1. Enbrel Inflammation $1,719 80 payments
  2. RINVOQ $1,530 77 payments
  3. Otezla $849 45 payments
  4. SIMPONI ARIA $784 50 payments
  5. Cimzia $730 37 payments
  6. COSENTYX Immunology $557 32 payments
  7. TREMFYA $512 27 payments
  8. COSENTYX Dermatology $511 30 payments
  9. Zilretta $498 4 payments
  10. Enbrel Inflammation $362 27 payments
  11. Other $4,624 259 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,588

Median for Physician Assistant: 241

Drug cost

$698,165

Median for Physician Assistant: $4,110

Branded share of claims

33.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 34 $246,617
Taltz Autoinjector Ixekizumab Brand 21 $147,669
Enbrel Sureclick Etanercept Brand 19 $140,726
Orencia Clickject Abatacept Brand 20 $111,830
Hydroxychloroquine Sulfate Generic 426 $22,235
Methotrexate Methotrexate Sodium Brand 424 $10,953
Leflunomide Generic 128 $9,022
Leucovorin Calcium Generic 112 $4,395
Colchicine Generic 21 $1,341
Allopurinol Generic 127 $744

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$23,686

Of which drugs: $202

Medicare patients

138

Average age 76

Services billed

760

114 women, 24 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 68%
Chronic kidney disease 42%
Depression 25%
Ischemic heart disease 24%
Diabetes 21%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 42 162 $125

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Enbrel
  • Amgen Inc. $308
$308 19 —
COSENTYX
  • Novartis Pharmaceuticals Corporation $271
$271 — —
RINVOQ
  • AbbVie, Inc. $168
$168 — —
ORENCIA
  • E.R. Squibb & Sons, L.L.C. $158
$158 20 —
SKYRIZI
  • AbbVie, Inc. $139
$139 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

514 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record